PT-141
Also known as: Bremelanotide, Vyleesi
Buy in shop
PT-141 from $74/kit
4 verified vendors, ≥99% purity, COAs included.
Key Facts: PT-141
- Category
- Sexual Health
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - HSDD in premenopausal women
- Administration
- Subcutaneous injection (autoinjector available)
- Typical Dose
- 1.75 mg as needed
- Frequency
- As needed, at least 45 min before activity
- Duration
- As needed, at least 45 min before activity
Mechanism of Action
Bremelanotide activates melanocortin receptors in the brain, mainly MC4R with some MC3R activity, in the hypothalamus. Unlike PDE5 drugs such as sildenafil that work on blood flow in the genitals, PT-141 acts centrally on the neural circuits that generate sexual desire and arousal, so its effect does not depend on hormone levels or direct physical stimulation. That same MC4R activity is why nausea is its most common side effect, and why it can transiently raise blood pressure and lower heart rate, which shaped its dosing limits.
Research Summary
PT-141 has some of the strongest evidence of any peptide on the gray market because it went through a full FDA program. The pivotal data come from the two identical phase 3 RECONNECT trials by Kingsberg and colleagues, published in Obstetrics and Gynecology in 2019, which randomized 1,267 premenopausal women with HSDD to 1.75 mg subcutaneous bremelanotide as needed or placebo. Both trials showed statistically significant improvements in sexual desire and in distress over low desire (both P less than 0.001), though the real-world benefit is modest: the effect size on desire scores was roughly 0.3 to 0.6, and the gain in satisfying sexual events over placebo was small. Nausea affected around 40 percent of women and was the leading reason people stopped, and dosing is capped at eight doses per month. Use in men for libido or erectile dysfunction is off-label and far less rigorously studied than the approved female HSDD indication.
Dosing Information
Typical Dosingⓘ
Community experience
1.75 mg as needed
0.5-2 mg per dose
As needed, at least 45 min before activity
FDA-approved dose is 1.75 mg. Not for daily use - max 8 doses per month. Can cause nausea and flushing.
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
1.75 mg (FDA approved for women)
Research doses for men varied
Duration
As needed, at least 45 min before activity
Administration
Subcutaneous injection (autoinjector available)
Timing & Administration
Best Time to Take
1-2 hours before sexual activity
As needed, max once per 24 hours
Food Recommendation
With or without food
Why This Timing?
PT-141 (Bremelanotide) takes 45-60 minutes to work. Timing before anticipated activity is optimal.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea (40% - most common)
- ●Facial flushing (20%)
- ●Injection site reactions
- ●Headache
- ●Transient blood pressure increase
- ●Skin hyperpigmentation with frequent use
- ●Vomiting
- ●Fatigue
- ●FDA approved (Vyleesi) for HSDD in women
References
- https://pubmed.ncbi.nlm.nih.gov/31599840/
- https://pubmed.ncbi.nlm.nih.gov/35230162/
- https://clinicaltrials.gov/study/NCT02333071
- https://pubmed.ncbi.nlm.nih.gov/11018622/
Research This Peptide Further
Buy in shop
PT-141 from $74/kit
4 verified vendors, ≥99% purity, COAs included.
Frequently Asked Questions
What does PT-141 do?
PT-141, generic name bremelanotide and sold as Vyleesi, is a melanocortin peptide and a cyclic analog of alpha-MSH that works in the brain to boost sexual desire. It is genuinely FDA approved: in June 2019 it became the first on-demand treatment for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is also used off-label for low libido and erectile dysfunction in men.
How does PT-141 work?
Bremelanotide activates melanocortin receptors in the brain, mainly MC4R with some MC3R activity, in the hypothalamus. Unlike PDE5 drugs such as sildenafil that work on blood flow in the genitals, PT-141 acts centrally on the neural circuits that generate sexual desire and arousal, so its effect does not depend on hormone levels or direct physical stimulation. That same MC4R activity is why nausea is its most common side effect, and why it can transiently raise blood pressure and lower heart rate, which shaped its dosing limits.
Is PT-141 FDA approved?
Yes, PT-141 is FDA approved. FDA Approved - HSDD in premenopausal women
What are the side effects of PT-141?
Reported side effects include: Nausea (40% - most common), Facial flushing (20%), Injection site reactions, Headache, Transient blood pressure increase. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of PT-141?
Community-reported common dose: 1.75 mg as needed (As needed, at least 45 min before activity). Range: 0.5-2 mg per dose. Administration: Subcutaneous injection (autoinjector available). Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with PT-141 or used in similar applications.
Melanotan II
ResearchMelanotan II is a synthetic copy of alpha-melanocyte-stimulating hormone (alpha-MSH), nicknamed the tanning peptide because it darkens skin without much sun. It also triggers erections and can blunt appetite, which is why it became the template for the FDA-approved drug bremelanotide (PT-141). Melanotan II itself is not approved by the FDA or EMA and is sold only as an unregulated research chemical.
Sexual HealthTirzepatide
FDATirzepatide is a single peptide that activates two receptors at once: GIP and GLP-1, the two main incretin hormones your gut releases after eating. It is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea, and it has produced the largest weight-loss numbers of any approved drug to date. Like semaglutide, this is a heavily trialed, fully approved medicine, not a gray-market research compound.
Weight LossLiraglutide
FDALiraglutide is a once-daily injectable GLP-1 receptor agonist, a synthetic peptide that shares about 97% of its sequence with the natural gut hormone GLP-1 but is engineered with a fatty acid chain so it survives in the body far longer. It is FDA-approved as Victoza for type 2 diabetes (2010) and as Saxenda for chronic weight management (2014), and is one of the most studied drugs in its class. As of 2024 a generic version is also FDA-approved.
Weight LossDulaglutide
FDADulaglutide (brand name Trulicity) is a once-weekly injectable GLP-1 receptor agonist made by fusing a modified GLP-1 peptide to a fragment of a human antibody, which is what lets it last a full week between shots. It is FDA-approved for type 2 diabetes and, notably, to reduce cardiovascular risk in adults with diabetes. The once-weekly dosing made it a major convenience step up from earlier daily and twice-daily agents.
Weight LossOxytocin
FDAOxytocin is a 9-amino-acid hormone made in the hypothalamus, famous as the chemistry behind labor contractions, breastfeeding, and social bonding. As an injectable drug it is FDA-approved to induce labor and control postpartum bleeding, but the intranasal 'love hormone' versions sold for trust, anxiety, and autism are experimental and the human results are genuinely mixed. The hype runs well ahead of the evidence.
HormonalZiconotide
FDAZiconotide is a real, FDA-approved painkiller pulled from the venom of a marine cone snail. It is not an opioid, and unlike morphine, people do not build tolerance to it over time. The catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning.
HealingWant updates on PT-141 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.